ALEC
Alector·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALEC
Alector, Inc.
A clinical-stage biotech company pioneering immuno-neurology and innate immuno-oncology
131 Oyster Point Blvd, Suite 600 , South San Francisco, California 94080
--
Alector, Inc., originally incorporated as a limited liability company in Delaware in May 2013, is a clinical-stage biopharmaceutical company. Groundbreaking immuno-neurology, a new treatment for neurodegeneration. Immunoneurology identifies immune dysfunction as the underlying cause of a variety of pathologies that are drivers of degenerative encephalopathy. They are developing therapies designed to counteract these conditions at the same time by restoring healthy immune function to the brain.
Company Financials
EPS
ALEC has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -0.41, beating expectations. The chart below visualizes how ALEC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALEC has released its 2025 Q3 earnings report, with revenue of 3.26M, reflecting a YoY change of -78.75%, and net profit of -34.67M, showing a YoY change of 17.89%. The Sankey diagram below clearly presents ALEC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
